TOTOWA, N.J., July 17, 2014 /PRNewswire/ -- BiologicTx® was selected as the specialty pharmacy for the observational treatment registry study to evaluate the long-term treatment effects of immune globulin intravenous (IGIV) maintenance therapy on donor specific antibodies (DSA) in renal transplant recipients. Study sponsors are Databean of Mount Vernon, NY and eMax Health of White Plains, NY.
The clinical trial involves ten leading Transplant Centers throughout the United States, led by Principal Investigators: Dr. Richard Knight, Director of Kidney and Pancreas Transplant, and Dr. A. Osama Gaber, Director of Transplantation at the J.C. Walter Jr. Transplant Center, Houston Methodist Hospital, Houston, TX, and Dr. Matthew Everly, of the Paul I. Terasaki Foundation Laboratory, Los Angeles, CA.
Sal Rafanelli, RPh, CEO and Co-Founder of BiologicTx said, "In our continued efforts to advance the science and clinical research within solid organ transplantation, we are extremely pleased that we were selected by the study sponsors to help execute this Donor Specific Antibody observational study." The study is supported by a research grant from Octapharma USA, Inc.
BiologicTx® is a national specialty pharmacy that joins the administration of therapeutics, research, and digital health to advance the practice of solid organ transplant and chronic specialties. BiologicTx is comprised of four operating segments: BiologicTx Pharmacy and Therapeutic Services; BiologicTx Clinical Trials™, which designs, sponsors, and aggregates clinical data, assisting in the publication of multicenter studies; BiologicTx Sequence™, a digital health platform, including clinical intelligence and data integration, supporting clinicians and patients in achieving optimal outcomes; and BiologicTx Paired Donation™, which offers an advanced software matching system, MatchGrid, and clinical decision intelligence to transplant centers. For more information, visit us at: www.BiologicTx.com.